@misc{indiciaee7398d1e47ca,
  title = {Phase 3 randomized trial evaluating second-line hormonal therapy versus docetaxel-estramustine combination chemotherapy on progression-free survival in asymptomatic patients with a rising prostate-specific antigen level after hormonal therapy for prostate cancer: an Eastern Cooperative Oncology Group (E1899), Intergroup/Clinical Trials Support Unit study.},
  author = {Janet R Walczak and Michael A Carducci and Eastern Cooperative Oncology Group E1899},
  year = {2003},
  doi = {10.1016/j.urology.2003.09.006},
  url = {https://pubmed.ncbi.nlm.nih.gov/14747052/},
  note = {Source identifier: 14747052}
}